|
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes |
Feb 2021 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) |
Feb 2021 |
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
|
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantat |
Feb 2021 |
Journal for immunotherapy of cancer |
Myelodysplastic Syndromes (MDS) |
|
Detectable mutations precede late myeloid neoplasia in aplastic anemia |
Feb 2021 |
Haematologica |
Aplastic Anemia |
|
Luspatercept in the treatment of lower-risk myelodysplastic syndromes |
Jan 2021 |
Future Oncology (London, England) |
Myelodysplastic Syndromes (MDS) |
|
Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options |
Jan 2021 |
Cancer Management and Research |
Myelodysplastic Syndromes (MDS) |
|
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? |
Jan 2021 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria |
Jan 2021 |
Leukemia |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
How I Treat Paroxysmal nocturnal hemoglobinuria |
Jan 2021 |
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes |
Jan 2021 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
